Cannabinoids as potential new therapy for the treatment of gliomas.

abstract：:Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies. We provide an overview on recent studies involving co...

journal_title：Expert review of neurotherapeutics

authors： Herholz SC,Herholz RS,Herholz K

更新日期：2013-11-01 00:00:00

abstract：:Millions of people worldwide suffer from diseases that result from a failure of central pathways to regulate behavioral and physiological processes. Advances in genetics and pharmacology have already allowed us to appreciate that rather than this dysregulation being systemic throughout the brain, it is usually rooted ...

journal_title：Expert review of neurotherapeutics

authors： Whittle AJ,Walsh J,de Lecea L

更新日期：2014-09-01 00:00:00

abstract：:Understanding of the structure and function of the endocannabinoid system is rapidly evolving. Physiological and pharmacological manipulations based on cannabinoid receptors, ligands and endocannabinoids have explained some medicinal attributes of cannabinoids as used across the world for thousands of years. Plant-der...

journal_title：Expert review of neurotherapeutics

authors： Holdcroft A,Patel P

更新日期：2001-09-01 00:00:00

abstract：:Trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are two of the most puzzling orofacial pain conditions and affected patients are often very difficult to treat. TN is characterized by paroxysms of brief but severe pain followed by asymptomatic periods without pain. In some patients a constant dul...

journal_title：Expert review of neurotherapeutics

authors： Obermann M,Holle D,Katsarava Z

更新日期：2011-11-01 00:00:00

abstract：:Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas. Notwithstanding a survival benefit in a subset of patients with high-grade gliomas, temozolomide (TMZ; Temodar®, Schering-Plough Pharmaceuticals, NJ, USA) is the primarily palliative treatment fo...

journal_title：Expert review of neurotherapeutics

authors： Chamberlain MC

更新日期：2010-10-01 00:00:00

abstract：INTRODUCTION:Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). The modern treatment era for MS witnessed a growing pool of drugs now available for use in clinical practice. These therapies work at different levels, however there is a lack of treatments acting on the neurode...

journal_title：Expert review of neurotherapeutics

authors： Ruggieri S,Tortorella C,Gasperini C

更新日期：2017-11-01 00:00:00

abstract：:Persistent gait deficits after stroke can cause falls, elevated energy cost and poor endurance. Coordination impairment is an underlying cause of gait deficits. Few efficacious interventions have been described that have targeted and measured restoration of coordinated gait components. Neuromuscular electrical stimula...

journal_title：Expert review of neurotherapeutics

authors： Daly JJ

更新日期：2006-10-01 00:00:00

abstract：:The prognosis for patients with malignant glioma, the most common primary intracranial neoplasm, remains dismal despite significant progress in neuro-oncological therapies and technology. This stems from the inability of current treatment strategies to address the highly invasive nature of this disease. Malignant glia...

journal_title：Expert review of neurotherapeutics

authors： Ehtesham M,Kabos P,Black KL,Yu JS

更新日期：2003-11-01 00:00:00

abstract：:Spasticity is a common complication of CNS injury and a cause of considerable discomfort and disability for the patient and difficulty for caregivers. It is estimated that over half a million people in the USA are affected by spasticity. In recent years, advances in the treatment of spasticity include the use of intra...

journal_title：Expert review of neurotherapeutics

authors： Sheean G

更新日期：2003-11-01 00:00:00

abstract：:Introduction: The microbiota-gut brain (MGB) axis is the bidirectional communication between the intestinal microbiota and the brain. An increasing body of preclinical and clinical evidence has revealed that the gut microbial ecosystem can affect neuropsychiatric health. However, there is still a need of further studi...

journal_title：Expert review of neurotherapeutics

authors： Iannone LF,Preda A,Blottière HM,Clarke G,Albani D,Belcastro V,Carotenuto M,Cattaneo A,Citraro R,Ferraris C,Ronchi F,Luongo G,Santocchi E,Guiducci L,Baldelli P,Iannetti P,Pedersen S,Petretto A,Provasi S,Selmer K,Sp

更新日期：2019-10-01 00:00:00

abstract：:The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010-2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizum...

journal_title：Expert review of neurotherapeutics

authors： Deiß A,Brecht I,Haarmann A,Buttmann M

更新日期：2013-03-01 00:00:00

abstract：:The saga of harmful administration of levodopa (LD) in the treatment of Parkinson's disease (PD) resulted from outcomes of animal trials and cell culture studies. They were initiated after the clinical observation of onset of motor complications related to the short plasma half-life of the drug in PD patients. This di...

journal_title：Expert review of neurotherapeutics

authors： Müller T

更新日期：2008-06-01 00:00:00

abstract：:With improved control of the immunological phenomena of systemic lupus erythematosus, the epidemiology of this disease is changing. While both cardiac and neurological manifestations of systemic lupus erythematosus have been consistently described, there is increasing awareness of the need for general cardiovascular p...

journal_title：Expert review of neurotherapeutics

authors： Wierzbicki AS

更新日期：2002-05-01 00:00:00

abstract：:Stroke is the third leading cause of mortality in the USA and one of the leading causes of severe morbidity. It is important to provide stroke patients and physicians with the most accurate prognostic information to optimize care and allocation of healthcare resources. Reliable prognostic markers available during the ...

journal_title：Expert review of neurotherapeutics

authors： Katan M,Elkind MS

更新日期：2011-02-01 00:00:00

abstract：:Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of A...

journal_title：Expert review of neurotherapeutics

authors： Pascual J,Vila C

更新日期：2019-08-01 00:00:00

abstract：:Currently approved medications to treat cognitive deficits in Alzheimer's disease are targeting relatively late neurotransmission alterations and, thus, new approaches are needed to improve the observed modest efficacy. Employing various combinations of existing drugs is one way to achieve this aim. We can attempt to ...

journal_title：Expert review of neurotherapeutics

authors： Sobow T

更新日期：2010-05-01 00:00:00

abstract：:This review evaluates the most recent evidence available on the potential of cannabinoid drugs to relieve spasticity and pain in multiple sclerosis. Many different drugs are used to control the symptoms of multiple sclerosis, periods of relapse and the progression of the disease but it is in the potential management o...

journal_title：Expert review of neurotherapeutics

authors： Smith PF

更新日期：2003-05-01 00:00:00

abstract：:Cluster headache is one of the primary headache disorders. It is considered the most severe headache syndrome known to humans. In most instances, this disorder is readily treatable when the correct medications are utilized at the correct dosages. Cluster headache treatment involves abortive, transitional and preventiv...

journal_title：Expert review of neurotherapeutics

authors： Rozen TD

更新日期：2002-05-01 00:00:00

abstract：INTRODUCTION:Friedreich ataxia (FRDA) is a progressive, inherited, neurodegenerative disease for which there is currently no cure or approved treatment. FRDA is caused by deficits in the production and expression of frataxin, a protein found in the mitochondria that is most likely responsible for regulating iron-sulfur...

journal_title：Expert review of neurotherapeutics

authors： Strawser C,Schadt K,Hauser L,McCormick A,Wells M,Larkindale J,Lin H,Lynch DR

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:The underlying etiology of tension type headache (TTH) is not understood. The current paper highlights the etiologic role of muscle trigger points (TrPs) to the development and maintenance of central sensitization in TTH and its clinical repercussion for proper management of these patients. Areas covered: ...

journal_title：Expert review of neurotherapeutics

authors： Fernández-De-Las-Peñas C,Arendt-Nielsen L

更新日期：2017-09-01 00:00:00

abstract：:The kynurenine pathway has received increasing attention as its connection to inflammation, the immune system and neurological conditions has become more apparent. It is the primary route for tryptophan catabolism in the liver and the starting point for the synthesis of nicotinamide adenine dinucleotide in mammals. Dy...

journal_title：Expert review of neurotherapeutics

authors： Davis I,Liu A

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Chronic inflammatory neuropathies are disorders caused by an immune response to peripheral nerve. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN) and neuropathy associated with anti-MAG IgM monoclonal gammopathy and other less frequent neurop...

journal_title：Expert review of neurotherapeutics

authors： Nobile-Orazio E,Gallia F,Terenghi F,Bianco M

更新日期：2017-08-01 00:00:00

abstract：:Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest ...

journal_title：Expert review of neurotherapeutics

authors： Hill SK,Bishop JR,Palumbo D,Sweeney JA

更新日期：2010-01-01 00:00:00

abstract：:The need for maintenance therapy in patients with major depressive disorder (MDD) is underscored by the high likelihood of recurrence after short-term treatment. Current recommendations include treatment to remission and long-term treatment to prevent relapse and recurrence. This article will summarize the design and ...

journal_title：Expert review of neurotherapeutics

authors： Kornstein SG

更新日期：2008-05-01 00:00:00

abstract：INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

journal_title：Expert review of neurotherapeutics

authors： Khan A,Corbett A,Ballard C

更新日期：2017-07-01 00:00:00

abstract：:Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its...

journal_title：Expert review of neurotherapeutics

authors： Makke Y,Abou-Khalil B

更新日期：2019-10-01 00:00:00

abstract：:Introduction: Despite increased interest in the pharmacotherapy of bipolar disorder during pregnancy and the postpartum period, management of the disorder during these critical periods in a woman's life remains challenging.Areas covered: The authors review the effect of pregnancy and the postpartum period on the cours...

journal_title：Expert review of neurotherapeutics

authors： Sharma V,Sharma P,Sharma S

更新日期：2020-04-01 00:00:00

abstract：INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

journal_title：Expert review of neurotherapeutics

authors： Amanatkar HR,Papagiannopoulos B,Grossberg GT

更新日期：2017-01-01 00:00:00

abstract：:Braak's proposal that, in patients with Parkinson's disease, Lewy bodies and neurites progressively invade the brain through regions connected to autonomic and olfactory centers remains contentious. Confounding factors include the lack of an in vivo marker to examine the progression of Lewy pathology, the retrospectiv...

journal_title：Expert review of neurotherapeutics

authors： Halliday G,McCann H,Shepherd C

更新日期：2012-06-01 00:00:00

abstract：:Recent evidence suggests that active trigger points (TrPs) in neck and shoulder muscles contribute to tension-type headache. Active TrPs within the suboccipital, upper trapezius, sternocleidomastoid, temporalis, superior oblique and lateral rectus muscles have been associated with chronic and episodic tension-type hea...

journal_title：Expert review of neurotherapeutics

authors： Alonso-Blanco C,de-la-Llave-Rincón AI,Fernández-de-las-Peñas C

更新日期：2012-03-01 00:00:00